Abstract |
Metastatic medullary thyroid cancer (MTC) responds poorly to conventional treatments with chemotherapy and radiotherapy. Gene therapy--the transfer of genetic material for therapeutic purposes--might have therapeutic potential for patients with progressive metastatic MTC that is incurable by conventional treatments. To date, a number of gene-therapy strategies have been explored, primarily those that use replication-deficient adenovirus vectors to transfer therapeutic genes to tumor cells. Tissue-specific expression of the promoter for calcitonin and calcitonin-related polypeptide alpha has allowed therapeutic genes to be specifically expressed in calcitonin-secreting cells and in the MTC tumors derived from them; such tissue-specific expression contributes to improved safety of gene therapies and has the potential to increase their therapeutic index. In addition, the identification of an MTC-specific peptide ligand raises the possibility of developing an MTC-selective vector. In this article, we have described the exciting area of gene therapy in the management of MTC with a focus on preclinical in vitro and in vivo MTC models.
|
Authors | Marinella Messina, Bruce G Robinson |
Journal | Nature clinical practice. Endocrinology & metabolism
(Nat Clin Pract Endocrinol Metab)
Vol. 3
Issue 3
Pg. 290-301
(Mar 2007)
ISSN: 1745-8366 [Print] England |
PMID | 17315037
(Publication Type: Journal Article, Review)
|
Topics |
- Carcinoma, Medullary
(therapy)
- Clinical Trials as Topic
- Combined Modality Therapy
- Gene Targeting
- Genetic Therapy
(methods)
- Humans
- Immunotherapy
(methods)
- Thyroid Neoplasms
(therapy)
|